The Latin America, Middle East and Africa Sustained Release Excipients Market would witness market growth of 11.4% CAGR during the forecast period (2022-2028).
The increased physician comfort with the potential of continuous drug release to produce appropriate blood levels has also made the sustained release drug delivery systems practitioners preferred. There are numerous current initiatives to enhance the therapeutic effectiveness, bioavailability, and patient compliance of oral medications. To satisfy the increasing needs, numerous sustained-release oral medication delivery techniques have been created.
The market is being driven by an increase in the number of licensing agreements that have been signed for the generation of controlled-release medication forms in therapeutic applications such as oncology, oral vaccines, and CNS. Furthermore, because there are no delivery methods specially created for the juvenile population, they need distinct oral drug delivery systems from other segments of the population.
As a result, adult dose forms already in use are modified to treat juvenile patients. Various disorders that affect the elderly are treated with the help of sustained release medication delivery forms. Through the use of these drug-delivering devices, adherence to the medications can likewise be easily monitored.
Latin America to the fore of the region's health policies. This would enable both raising awareness about the bad quality of life that these diseases bring and recognition of better medication to be employed for treatment. Similarly, CVD is the leading cause of mortality in Brazil, which has resulted because of two reasons. The first is the development of urbanization- and globalization-related lifestyle changes, such as increased calorie consumption and decreased energy expenditure. The other is the quick aging of the population brought on by higher life expectancies and decreasing fertility.
The Brazil market dominated the LAMEA Sustained Release Excipients Market by Country in 2021; thereby, achieving a market value of $34.5 million by 2028. The Argentina market would exhibit a CAGR of 12% during (2022 - 2028). Additionally, The UAE market is estimated to witness a CAGR of 11.1% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Oral, Transdermal, Vaginal, Intravenous, Ophthalmic, Subcutaneous, Intramuscular, and Others. Based on Product, the market is segmented into Polymers, Minerals, Sugars, Gelatin & Chitosan, and Others. Based on Technology, the market is segmented into Targeted Delivery, Implants, Wurster Technique, Transdermal, Micro Encapsulation, and Coacervation & Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Sustained Release Excipients Market is Predict to reach $1.9 Billion by 2028, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BASF SE, International Flavors & Fragrances, Inc., Ashland Global Holdings Inc., Evonik Industries AG, Croda International Plc, Gattefossé, Merck Group, Pfizer, Inc., Novartis AG and AstraZeneca Plc.
By Route of Administration
By Product
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
